Treatment of chronic proliferative cholangitis with c-myc shRNA

Table 1 HYP content and expression level of c-myc, PCNA, mucin5AC, procollagen III

	CPC	shRNA-1	shRNA-2	shRNA-3	NC	SO
c-myc/GAPDH	6.21 ± 1.97	2.37 ± 0.77	2.93 ± 0.84	0.97 ± 0.28	6.57 ± 2.11	0.22 ±
P	< 0.0001	0.001	< 0.0001		< 0.0001	< 0.0001
PCNA/β-actin	3.20 ± 0.81	1.52 ± 0.28	1.83 ± 0.42	0.82 ± 0.22	2.71 ± 0.63	0.45 ± 0.08
P	< 0.0001	0.013	0.005		0	0.011
Mucin5AC/GAPDH	1.87 ± 0.47	0.96 ± 0.28	1.05 ± 0.30	0.42 ± 0.16	1.69 ± 0.41	0.12 ± 0.04
P	< 0.0001	0.004	0.002		< 0.0001	< 0.0001
Procol-III/β-actin	4.79 ± 1.27	2.83 ± 0.85	2.39 ± 0.58	1.23 ± 0.35	5.40 ± 1.76	0.52 ± 0.13
P	0	0.001	0.006		< 0.0001	0.001
HYP content	1.29 ± 0.32	0.78 ± 0.16	0.83 ± 0.18	0.55 ± 0.13	1.41 ± 0.36	0.39 ± 0.08
P	0.003	0.041	0.028		0.001	0.038

P value was compared with c-myc shRNA-3 treatment group.